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Abstract 
Objective: The aim of this study was to investigate the feasibility of a large-scale 
trial to test the effectiveness of Google Maps application in order to improve the 
evaluation of Ambulation Score (AS) and the related EDSS in clinical practice. 
Background: AS is the most used scale to assesses gait impairment in people with 
Multiple Sclerosis (pwMS). AS relies mostly on the maximum distance a patient 
can walk without rest (maximum walking distance, MWD). In clinical practice 
doctors traditionally rely on patients’ estimates concerning the walked distance. 
Several studies showed the inaccuracy of such distance estimates and therefore the 
unreliability of disability assessment in clinical practice. 
Design/Methods: 243 pwMS were recruited in five Italian MS Centers. 
We collected 1. demographical and clinical data ; 2. the AS based on pwMS 
referred MWD (perceived AS, pAS) and, consequently, the perceived EDSS 
(pEDSS); 3) the AS based on MWD identified on Google Maps (gmAS) and, 
consequently, the google maps EDSS (gmEDSS). We evaluated the agreement 
between the two latter measurements and whether demographic and clinical data 
might have influenced the agreement. Finally, in a subgroup of 75 pwMS we 
evaluated an actual AS (actAS), objectively measured, and we tested the 
agreement among the pAS, the gmAS and the actAS. 
Results: pEDSS and gmEDSS were coincident in 169/243 (69.55%) pwMS. In 
74/243 (30,45%) were different (higher/lower). These two groups were 
significantly different for FSS (p= 0.01) and PHQ-9 (p = 0.002) and frequency of 
progressive phenotype (OR = 2.8, 95% CI 1.1 – 7.11, p = 0.03). The pEDSS and 
the actEDSSwere coincident in 45.3% of pwMS. gmEDSS and the actEDSS were 
coincident in 57.3% 
Conclusions: In conclusion, we suggest that Google Maps application could be 
easily applied in a real-life clinical setting to calculate the AS and that is suitable 
to be evaluated in future clinical studies. 
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